Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (78)

I-003Katrine Agergaard

Population pharmacokinetic modelling of whole blood and intracellular tacrolimus in adult kidney transplanted patients

Wednesday 10:20-11:50

I-004Jurij Aguiar Zdovc

Population pharmacokinetic-pharmacodynamic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis

Wednesday 10:20-11:50

I-006Karam Alali

Population pharmacokinetic Models of regular SC insulin for hyperglycemia following acute ischemic stroke among patients with and without pre-existing diabetes mellitus

Wednesday 10:20-11:50

I-020Irina Baltcheva

Do more with less: Model-informed dosing rationale of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)

Wednesday 10:20-11:50

I-025Maxime Beaulieu

Evusheld hastens viral clearance in COVID-19 hospitalized patients: a modeling analysis of the randomized DisCoVeRy trial

Wednesday 10:20-11:50

I-027Massinissa Beldjenna

Development of a multi-endpoint mechanistic pharmacokinetic-pharmacodynamic model describing CD40 antagonism in autoimmune diseases.

Wednesday 10:20-11:50

I-029Amina Bensalem

Concentration-effect relationship of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in healthy Beagle dogs

Wednesday 10:20-11:50

I-033Daniele Boaretti

Towards an integrated mPBPK/PD model for drug-optimization and prediction of relapse after treatment of tuberculosis in mice

Wednesday 10:20-11:50

I-036Chloé Bracis

Mechanisms of ART-free virus control of SHIV with AAV gene therapy delivery of eCD4Ig

Wednesday 10:20-11:50

I-042Divakar Budda

A comprehensive binding kinetic model for morphine in the pain matrix regions: what are the most important physiological factors for morphine µ-OR occupancy?

Wednesday 10:20-11:50

I-050Kangna CAO

A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages

Wednesday 10:20-11:50

I-052Bibiana CARDOZO

PKPD Relationship between THC Levels and Self-Assessment of Driving Proficiency Among Cannabis Users

Wednesday 10:20-11:50

I-059Akshita Chawla

Comparative assessment of incretin therapies on weight loss through a model-based meta-analysis approach

Wednesday 10:20-11:50

I-066Maxwell Chirehwa

Designing Phase II studies for optimal Phase III dosing/regimen selection using end-to-end DETER modelling

Wednesday 10:20-11:50

I-081Kristof De Vos

In vitro-in silico platform for mechanistic investigation of bile acid disposition in cultured hepatocytes

Wednesday 10:20-11:50

I-087Alessandro Di Deo

Model-based evaluation of predictive markers of response to adalimumab in juvenile idiopathic arthritis

Wednesday 10:20-11:50

I-089Nada Dia

Model-informed comparison of the clinical relevance of four renal function markers on meropenem target attainment in critically ill septic patients

Wednesday 10:20-11:50

I-090Cheikh Diack

Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema

Wednesday 10:20-11:50

I-095Vincent Duval

Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with moderate-to-severe atopic dermatitis.

Wednesday 10:20-11:50

I-098Omar Elkayal

Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis

Wednesday 10:20-11:50

I-105Floris Fauchet

Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with Prurigo Nodularis

Wednesday 10:20-11:50

I-108Rebekka Fendt

A virtual ulcerative colitis patient population to explore combination treatments in in silico clinical trials

Wednesday 10:20-11:50

II-001Edoardo Faggionato

Use of the Minimally-Invasive Oral Minimal Model to Quantify the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals with Type 1 Diabetes under Free-living Conditions

Wednesday 15:20-16:50

II-002Maite Garraza Obaldia

Semi-mechanistic model of pulmonary ventilation changes during propofol and remifentanil infusion as measured by minute-volume and transcutaneous pCO2.

Wednesday 15:20-16:50

II-017Jeremie Guedj

Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection

Wednesday 15:20-16:50

II-036Maud Hennion

Population Pharmacokinetic Model of Ixodes ricinus-Contact Phase Inhibitor for patients with Spontaneous Intracerebral Haemorrhage

Wednesday 15:20-16:50

II-040Yannick Hoffert

Model-informed intravenous-to-subcutaneous switching of infliximab in patients with inflammatory bowel diseases

Wednesday 15:20-16:50

II-062Martin Johnson

Understanding onset and response of two key endpoints in Systemic Lupus Erythematosus

Wednesday 15:20-16:50

II-063Shreyas Joshi

A multiscale framework for predicting the evolution of SARS-CoV-2 in response to vaccination and interventions.

Wednesday 15:20-16:50

II-073Anne Keunecke

Case study of Exposure-Safety analysis in Phase 1 oncology – lessons learned

Wednesday 15:20-16:50

II-080Matthias König

Captopril in Focus: Establishing an Open Pharmacokinetic Dataset and PBPK Modeling

Wednesday 15:20-16:50

II-085Victoria Kulesh

A mechanistic model of thymocyte dynamics: a quantitative tool for predicting drug effects on thymic function

Wednesday 15:20-16:50

II-086Pietro Laddomada

Dose rationale and metrics of target exposure for tacrolimus and mycophenolate in paediatric patients undergoing solid organ transplantation

Wednesday 15:20-16:50

II-087Jennifer Lang

Development of a population pharmacokinetic/pharmacodynamic model of lepodisiran, a small interfering RNA targeting lipoprotein(a), in healthy adults

Wednesday 15:20-16:50

II-100Raphaëlle Lesage

A quantitative system toxicology model of thyroid hormones for assessment of species differences in thyroid toxicity

Wednesday 15:20-16:50

II-101Giulia Lestini

Population pharmacokinetics and pharmacodynamics modeling of complement biomarkers and endpoints in C3 glomerulopathy (C3G) patients treated with iptacopan (FABHALTA®)

Wednesday 15:20-16:50

II-102Yingxue Li

Population Pharmacokinetic Modelling of Norepinephrine in Healthy Volunteers Prior to and During General Anesthesia

Wednesday 15:20-16:50

II-104Yu-wei Lin

Assessing the impact of choosing different estimated glomerular filtration rate (eGFR) equations on pharmacokinetic models: A proof-of-concept study with illustrative examples

Wednesday 15:20-16:50

II-116Esther Lubberts

The potential of modeling and simulation as support for generic long-acting injectable (LAI) marketing authorization applications

Wednesday 15:20-16:50

III-010Hadija Marchiori

A Nonlinear Mixed Effect model of the LNA-i-miR-221 kinetics in rats for predicting key parameters of human kinetics via allometric scaling

Thursday 09:50-11:20

III-013Eleonora Marostica

Population analysis of MG-ADL total score for efgartigimod Phase 3 study in myasthenia gravis patients: application of a bounded-integer model

Thursday 09:50-11:20

III-020Denis Menshykau

Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases.

Thursday 09:50-11:20

III-026Adrien Mitard

Modelling antibody levels impact on infection and SARS-CoV2 replication

Thursday 09:50-11:20

III-028Juma Ayubu MOHAMEDI

Cumulative exposure to infliximab during induction therapy predict remission in patients with Crohn’s disease and ulcerative colitis

Thursday 09:50-11:20

III-031James Morse

Sevoflurane Pharmacokinetics and Pharmacodynamics in Adults During General Anaesthesia

Thursday 09:50-11:20

III-035Supichaya Narongchartsopon

Implications of the changes in the pharmacokinetics of raltegravir in pregnant and post-partum women undergoing antiretroviral therapy against HIV infection.

Thursday 09:50-11:20

III-038Bach NGUYEN

Mechanistic model of antibody response, SARS-CoV-2 viral loads and genetic mutation burden to optimise molnupiravir dosing

Thursday 09:50-11:20

III-041Antonina Nikitich

An integrative physiologically-based model of T lymphocyte homeostasis and exogenously administered T cell kinetics

Thursday 09:50-11:20

III-047Katharina Och

Evaluation of a pharmacokinetic model of certoparin in patients with deep vein thrombosis and severe renal insufficiency

Thursday 09:50-11:20

III-051David Outland

Towards a vertex based mechanical model of vascular endothelial cell morphology in the context of the interaction of blood flow and vascular geometry

Thursday 09:50-11:20

III-052Joanneke Overbeek

Population pharmacokinetics of cobicistat in once and twice daily regimens in various populations

Thursday 09:50-11:20

III-054Eirini Panoilia

A model based meta-analysis of the placebo response for EASI and pruritus NRS scores in moderate to severe atopic dermatitis

Thursday 09:50-11:20

III-061Anu Patel

Comparison of oxazolidinones’ exposure-response for the treatment of tuberculosis

Thursday 09:50-11:20

III-064Zorica Pejčić

Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite

Thursday 09:50-11:20

III-089Silke Retlich

Leveraging Model-Based Meta-Analysis to Benchmark Chronic Kidney Disease Treatments: A Focus on Kidney Function and Proteinuria Endpoints

Thursday 09:50-11:20

III-105Ayatallah Saleh

Evaluating the contribution of Urine Data to PopPK Models in Renal Impairment: A Case Study

Thursday 09:50-11:20

IV-007Anastasios Siokis

In-silico clinical trials in virtual asthma patients powered by QSP accelerated the development of lunsekimig

Thursday 15:00-16:30

IV-008Lucia Siovitz

Characterizing the Longitudinal Exposure-Response Relationship of Upadacitinib Efficacy in Vitiligo: Insights from Analysis of Phase 2 Clinical Data

Thursday 15:00-16:30

IV-015Angelica Squarzoni

Pharmacodynamic Drug-Drug Interaction Between Oxaliplatin and HDAC Inhibitors in Colorectal Cancer Cell Lines

Thursday 15:00-16:30

IV-021Ida Storgaard

Population pharmacokinetic-pharmacodynamic model of subcutaneous bupivacaine in a novel extended-release microparticle formulation

Thursday 15:00-16:30

IV-022Hong Su

How should target-mediated drug disposition model be used for predicting receptor occupancy?

Thursday 15:00-16:30

IV-038Charlotte M Thomas

Pharmacokinetic-Pharmacodynamic Modelling of Risankizumab in Plaque Psoriasis Real World Data

Thursday 15:00-16:30

IV-039Anders Thorsted

Item response theory-enabled translation between DAS28 and ACR – Key clinical endpoints within rheumatoid arthritis drug development

Thursday 15:00-16:30

IV-040Paul Thoueille

Pharmacometrics-based analysis of salmeterol and its metabolite α-hydroxysalmeterol in plasma and urine: practical implications for doping control

Thursday 15:00-16:30

IV-041Johannes Tillil

Automated QSP model order reduction combining multiple state-level reduction approaches

Thursday 15:00-16:30

IV-047Anastasia Tsyplakova

Population Pharmacokinetics of Valproic Acid, Lamotrigine, and Levetiracetam in the Pediatric Population

Thursday 15:00-16:30

IV-049Debra van Asten

Population pharmacokinetics of ticagrelor and its active metabolite in a real-life hospitalized population

Thursday 15:00-16:30

IV-050Stijn van Beek

Population pharmacokinetic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis

Thursday 15:00-16:30

IV-051Marinda van de Kreeke

Quantifying the sensitivity and specificity of CYP450 probe drugs in predicting in vivo enzyme activity under (patho)physiological conditions

Thursday 15:00-16:30

IV-054Tamara van Donge

Population PK modeling of Vamikibart in aqueous humor, an anti-IL-6 monoclonal antibody, in patients with diabetic and uveitic macular edema

Thursday 15:00-16:30

IV-070Umberto Villani

Model-based characterisation of host-directed therapeutics against M. tuberculosis in an in vitro experimental model

Thursday 15:00-16:30

IV-079Zhigang Wang

Time-to-event modelling and simulation of the risk of relapse after infusion interval extension of infliximab in patients with inflammatory bowel diseases

Thursday 15:00-16:30

IV-084Dominic Whittaker

Leveraging in vitro data from novel drug candidates to prioritize antibody combinations in autoimmune disease using a QSP model of IBD

Thursday 15:00-16:30

IV-097Liang Yang

A combined model meta-analysis of aggregated and individual FEV1 data from randomized COPD trials

Thursday 15:00-16:30

IV-098Eunsol Yang

Translational tool-based phase 2 clinical outcome predictions of the novel diarylquinoline TBAJ-587 for the treatment of tuberculosis, compared to bedaquiline and TBAJ-876

Thursday 15:00-16:30

IV-102Javier Zarzoso Foj

Individualized dosing regimen optimization of ustekinumab through a population pharmacokinetic-pharmacodynamic model in patients with psoriasis

Thursday 15:00-16:30

IV-103Tatiana Zasedateleva

Local TMDD of large molecules in tissue interstitial space

Thursday 15:00-16:30

IV-107Tan Zhang

The impact of drug properties and severity of obesity on renal clearance through glomerular filtration and active tubular secretion

Thursday 15:00-16:30